Rifaximin Production Cost Reports

The report provides a detailed analysis essential for establishing a rifaximin production plant. It encompasses all critical aspects necessary for rifaximin production, including the cost of rifaximin production, rifaximin plant cost, rifaximin production costs, and the overall rifaximin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a rifaximin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Rifaximin is an antibiotic that works locally in the gut with minimal systemic exposure. It is used to treat traveller’s diarrhoea caused by non-invasive E. coli in adults and children 12+. It is also utilised in irritable bowel syndrome with diarrhoea (IBS-D) via 2-week courses that reduce bloating and pain for up to 10 weeks. It is used to prevent recurrent overt hepatic encephalopathy (HE) episodes in liver disease patients by lowering ammonia-producing gut bacteria. It is employed in small intestinal bacterial overgrowth (SIBO), uncomplicated diverticular disease, recurrent Clostridium difficile infection and inflammatory bowel disease flares. Its common side effects include nausea, headache, abdominal pain or bloating, dizziness, fatigue, flatulence, constipation, peripheral edema, etc.

The market for rifaximin is driven by rising cases of gastrointestinal disorders like IBS-D and hepatic encephalopathy. Its demand for non-systemic antibiotics with minimal absorption and expanding approvals and reimbursement policies in the North America and Europe regions fuels its market. The ageing populations with liver disease, healthcare infrastructure improvements in Asia-Pacific, and R&D into novel formulations like oral suspensions expand its demand. The industrial rifaximin procurement is influenced by high API costs from specialised fermentation processes and reliance on Italian-origin manufacturers. Also, regulatory hurdles for purity and impurity profiles, supply chain stability amid global disruptions, and pricing pressures from branded and generics affect its market dynamics.

Raw Material for Rifaximin Production

According to the rifaximin production plant project report, the key raw materials used in the production of rifaximin include Amycolatopsis rifamycinfera, 2-amino-4-methylpyridine, ethanol, and acetone.

Production Process of Rifaximin

The extensive rifaximin production cost report consists of the following major industrial production process:

1. From Amycolatopsis rifamycinfera: The production of rifaximin starts with fermentation of Amycolatopsis rifamycinfera or similar strains to produce rifamycin O. This is extracted from the broth using organic solvents like ethyl acetate, purified, and isolated as the key intermediate. This rifamycin O then undergoes condensation with excess 2-amino-4-methylpyridine in a solvent mixture of water, ethanol, and acetone that gives crude rifaximin precipitate. The crude product is purified by dissolution in a hot ethanol-water mixture, followed by crystallisation to give pure rifaximin as the final product.

Rifaximin is a semi-synthetic rifamycin antibiotic existing as an orange to brown crystalline powder with multiple polymorphic forms (α, β, γ, δ, ε). Its γ-form is most stable and humidity-resistant. It has a molecular formula of C₄₃H₅₁N3O₁₁ with a molecular weight of 785.9 g/mol. It has low water solubility varying by hydration state (β-form wetter, α/δ dehydrated). It has high lipophilicity (XLogP3 5.88-6.08), 11 hydrogen bond acceptors and donors and a polar surface area of 198.38 Ų. It is formulated as pink film-coated tablets for gut-localised action with minimal systemic absorption. All these physical and chemical properties makes it useful as an antibiotic.